Analysis shows FDG-PET parameters predict progression-free survival in relapsed/refractory large B-cell lymphoma, suggesting improved risk stratification for treatment outcomes.
Key Points
This study investigates the prognostic role of FDG-PET parameters in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.
FDG-PET-based analysis of patients with large B-cell lymphoma undergoing treatment with bispecific antibodies.
Evaluation of baseline and follow-up FDG-PET scans to assess metabolic activity.
Statistical analysis using Kaplan-Meier and Cox regression for risk stratification based on FDG-PET parameters.
46% overall response rate to bispecific antibodies with 24% achieving complete response.
Median progression-free survival was 3 months, while median overall survival was 7 months.
Lower FDG-PET SUV-peak values indicated a significantly reduced risk of progression and mortality.